Vertex tops Q1 profit estimates on robust demand for cystic fibrosis treatments

Vertex Pharmaceuticals (VRTX.O) beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its cystic fibrosis treatments.

Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation.